drugset / Trial / NCT00236119
Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis
Non-randomizedCrossoverOpen-labelTreatment
Summary
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
Timeline
- Start
- 2005-06
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lestaurtinib | Small molecule | 20 mg | Oral |
| Subject | lestaurtinib | Small molecule | 40 mg | Oral |
| Subject | lestaurtinib | Small molecule | 60 mg | Oral |
| Subject | lestaurtinib | Small molecule | 80 mg | Oral |